<DOC>
	<DOC>NCT02960607</DOC>
	<brief_summary>The purpose of this study is to investigate whether high-dose icotinib treatment beyond disease progression is beneficial for NSCLC patients who have EGFR mutation and who have responded to EGFR TKI.</brief_summary>
	<brief_title>High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirmed stage IIIB/IV NSCLC Investigator confirmed progression according RECIST 1.1 during previous icotinib treatment Patients whose tumors: are EGFR mutationpositive or T790M mutationnegative Performance status: WHO 02 Measurable disease according to RECIST 1.1 at least one measureable lesion .if only one measureable lesion, the biological nature must be confirmed by cytology or histology a single diameter of lesion could be measured by at least one of the following methods: Chest or abdominal computed tomography(CT)or magnetic resonance imaging(MRI),conventional methods of diameter at least 20mm diameter spiral CT OR at least 10mm ANC ≥ 1.5*109/L, Platelets ≥ 75*109/L, Hgb≥ 9g/dL, Alanine amino transferase ≤ 2 × Upper limit of normal (ULN), Alkaline phosphatase ≤ 2.5 × ULN (&lt; 5 × ULN if liver metastases), Serum Creatinine ≤ 1.5 × ULN Women of childbearing age must have a pregnancy test 7 days before treatment and the result were negative ,men of childbearing age: surgical sterilization or treatment during and after the end of three months to take contraceptive measures Patient must be able to comply with the protocol Patient with symptomatic central nervous system metastases Patient has known active hepatitis B or C, or HIV infection Pregnant or breastfeeding. Patient with uncontrolled undercurrent illness or circumstances that could limit compliance with the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>